1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported):
March 4, 2000
GELTEX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-26872 04-3136767
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
153 SECOND AVENUE, WALTHAM
MASSACHUSETTS, 02451 (Address of
principal executive office and zip code)
Registrant's telephone number, including area code:
(781) 290-5888
2
ITEM 5. OTHER EVENTS. The financial statements of GelTex Pharmaceuticals, Inc.
(the "Company") at December 31, 1999 and 1998 and for each of the three years in
the period ended December 31, 1999 together with the accompanying report of the
Company's independent auditors dated February 22, 2000, filed as exhibit 99.1 to
this report, are hereby incorporated by reference in this report.
Page 2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized, on this 3rd day of March, 2000.
GELTEX PHARMACEUTICALS, INC.
By: /s/ Mark Skaletsky
-------------------------------------
Mark Skaletsky
President and Chief Executive Officer
Date: March 3, 2000
Page 3
4
EXHIBIT INDEX
EXHIBIT SEQUENTIAL
NUMBER DESCRIPTION PAGE NUMBER
- ------- ----------- -----------
23.1 Consent of Ernst & Young LLP
23.2 Consent of PricewaterhouseCoopers LLP
99.1 GelTex Pharmaceuticals, Inc. Financial
Statements at December 31, 1999 and 1998
and for each of the three years in the period
ended December 31, 1999 and the report of
independent auditors. Filed herewith.
99.2 RenaGel LLC Financial Statements for the years
ended December 31, 1999 and 1998 and the period
June 6, 1997 (Date of Inception) through December
31, 1997 and the report of independent accountants.
Filed herewith.
Page 4